Massachusetts Financial Services Co. MA Raises Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Massachusetts Financial Services Co. MA raised its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 19.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 171,856 shares of the company’s stock after buying an additional 28,333 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.32% of Voyager Therapeutics worth $1,005,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Intech Investment Management LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter worth about $74,000. Empowered Funds LLC lifted its holdings in shares of Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its stake in shares of Voyager Therapeutics by 7.0% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company’s stock worth $801,000 after buying an additional 9,000 shares during the last quarter. Finally, Hunter Perkins Capital Management LLC raised its stake in Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after buying an additional 2,025 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $5.78 on Thursday. The stock has a market capitalization of $315.76 million, a price-to-earnings ratio of 7.99 and a beta of 0.89. Voyager Therapeutics, Inc. has a 1-year low of $5.19 and a 1-year high of $11.72. The business’s fifty day moving average price is $6.52 and its 200-day moving average price is $7.34.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the prior year, the company earned ($0.59) earnings per share. Equities research analysts anticipate that Voyager Therapeutics, Inc. will post -1.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on VYGR shares. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 18th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush decreased their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.00.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.